Strattera (atomoxetine) belongs to the group of drugs called selective norepinephrine reuptake inhibitors (SNRIs). It is used to treat depression, and also as a stimulant. It has a high affinity for dopamine receptors in the brain, and can be used for treatment of attention, hyperactivity, and other mental/mood disorders. Strattera is used to treat ADHD (Attention-Deficit/Hyperactivity Disorder).
Strattera (atomoxetine) is a type of medication known as a selective norepinephrine reuptake inhibitor (SNRI). This drug blocks the reuptake of norepinephrine, which causes an increase in the level of norepinephrine in the brain.
Strattera is used for treating adults and children 12 years of age and older who have Attention-Deficit/Hyperactivity Disorder (ADHD).
Strattera is also used for the treatment of ADHD (Attention-Deficit/Hyperactivity Disorder).
Strattera is a non-stimulant. It is a selective norepinephrine reuptake inhibitor (SNRI), which increases norepinephrine levels. This means that Strattera can make norepinephrine more available to the brain.
You should take Strattera at the same time as you take medication for depression and other mental/mood disorders.
Do not take Strattera if you have:
If you have taken Strattera for more than one year, you should consult a doctor or pharmacist.
If you are pregnant or breastfeeding, you should not take Strattera if you are pregnant or breast-feeding. Strattera can pass into breast milk.
Before you start treatment with Strattera, you should check your blood pressure. It can be affected by a number of different conditions:
If you have any of these conditions, talk to your doctor. You may need to stop using Strattera if you have any of these conditions.
The side effects of Strattera are usually mild. If they persist or worsen, you should contact your doctor.
Most side effects are temporary, and usually go away within a few days. However, if they are severe or don’t go away, you should contact your doctor.
The Food and Drug Administration is advising consumers not to purchase Strattera, the brand name for the drug ADHD, because of a possible link to an increased risk of heart attack and stroke. The FDA issued a black box warning for Strattera in July 2013, which warns of increased risk of heart attack and stroke, especially in older adults and those with a family history of heart disease. The FDA also noted a risk of stroke in patients with pre-existing heart conditions, particularly those with diabetes and high blood pressure. Strattera, known generically as atomoxetine, is an antidepressant medication used to treat attention-deficit hyperactivity disorder (ADHD). The drug was originally developed as an antidepressant, but it has since been found to increase the risk of heart attack and stroke in some patients. The FDA also notes that a small study of Strattera in young adults found that the drug had an increased risk of heart attack and stroke. The FDA recommends consumers not purchase Strattera because of concerns that the drug may increase the risk of heart disease in people with pre-existing heart conditions. The drug is available as Atomoxetine, a prescription medication for ADHD.
Strattera is a controlled substance used to treat attention-deficit hyperactivity disorder (ADHD).In 2012, the FDA added the black box warning to a new warning for Strattera, a drug used to treat ADHD. The black box warning identifies a risk of heart attack or stroke in people with pre-existing heart conditions, particularly those with diabetes and high blood pressure. The black box warning also notes an increased risk of stroke in patients with pre-existing heart conditions, particularly those with family history of heart disease. The FDA notes that Strattera is an important part of the treatment of ADHD and that it should be used only under the guidance and supervision of a healthcare professional. The black box warning applies to both children and adults. The FDA notes that the black box warning is not specific to Strattera. In addition, the black box warning also does not include information about the risk of stroke in people with pre-existing heart conditions. The FDA notes that the black box warning does not include information about the risk of heart disease in people with pre-existing heart conditions. The FDA notes that there is no FDA-approved medication for treating ADHD. Strattera is not approved for use in adults.
The FDA issued a black box warning for Strattera in July 2013, which lists heart-related deaths associated with the drug. The FDA notes that Strattera has been linked to an increased risk of heart attacks and stroke in people with pre-existing heart conditions. The FDA notes that patients with heart conditions that are related to heart disease should exercise caution when taking Strattera, especially in patients with pre-existing heart conditions. The FDA notes that the FDA recommends patients not purchase Strattera because of concerns that the drug may increase the risk of heart disease in people with pre-existing heart conditions. The black box warning does not include information about the risk of stroke in people with pre-existing heart conditions. The FDA notes that there is no FDA approved medication for treating ADHD.
The FDA has issued a black box warning for Strattera in July 2013. The FDA notes that Strattera has been linked to an increased risk of heart attack and stroke in people with pre-existing heart conditions.The FDA has issued a black box warning for Strattera in September 2013.
The FDA has issued a black box warning for Strattera in February 2014.
Introduction
Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI), which increases norepinephrine production by the neurons. By blocking norepinephrine reuptake, atomoxetine increases the amount of norepinephrine available in the brain, and thus, increases norepinephrine levels. The increased norepinephrine release and neurotransmitter production can cause improved mental performance, and thus, improve the mental well-being of individuals with attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The mechanism of action of atomoxetine is primarily related to its inhibition of norepinephrine reuptake and the subsequent increase in norepinephrine release. Atomoxetine also has the effect of enhancing the effects of norepinephrine and dopamine in the brain. The effects of atomoxetine may be different from that of norepinephrine.
Atomoxetine is primarily prescribed for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children. Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI), which increases norepinephrine availability in the brain, which may result in improved mental performance. Atomoxetine has been approved by the FDA in the treatment of ADHD. It is available in the form of tablets, oral capsules, and oral solution.
Atomoxetine is available in a variety of formulations. For instance, it is available as a generic medication and is available in tablet form and also as an oral solution. Atomoxetine is used in the treatment of ADHD and narcolepsy in children and adults with ADHD. Atomoxetine is approved by the FDA for the treatment of ADHD in children.
Atomoxetine is available in various forms such as oral tablets, oral suspension, and a solution for administration. The tablet form is suitable for children and adolescents who are at a high risk of developing ADHD. It is also suitable for adults who are at a low risk of developing ADHD. For those who need to take the tablet form of atomoxetine, atomoxetine is available in the form of oral suspension.
Atomoxetine is also available as a liquid medication. The liquid form of atomoxetine is also suitable for children and adolescents. It is also available in a variety of forms, such as tablets, capsules, and liquid suspensions. It is a generic drug, and the generic medication is available in the form of a tablet.
Atomoxetine has been found to be effective in the treatment of ADHD. Studies have shown that atomoxetine may have a positive effect on reducing ADHD symptoms in children. The medication is also approved by the FDA for the treatment of narcolepsy in children. Atomoxetine is a safe drug and has been prescribed by doctors to treat ADHD. It is also approved by the FDA for the treatment of narcolepsy in children.
Atomoxetine is available in various forms. It is also available as a tablet or liquid, a solution, and a suspension. In addition to the usual tablet form, atomoxetine can also be used as a liquid medication.
Atomoxetine is available as a capsule and can be used to treat ADHD, narcolepsy, and other conditions. It is also available in the form of a liquid solution. In addition to the usual form of atomoxetine, there are several other forms of atomoxetine available, including oral suspensions, tablets, capsules, and liquid solutions.
Atomoxetine is also used to treat ADHD in children and adults. It is approved by the FDA for the treatment of ADHD in children. Atomoxetine is also approved by the FDA for the treatment of narcolepsy in children. It is also approved by the FDA for the treatment of ADHD in adults.
Atomoxetine is available in various strengths and forms. For instance, it is available as a tablet or liquid, a solution, and a suspension. In addition to the usual forms, there are several other forms of atomoxetine available, such as a capsule and liquid, and in the form of tablets and suspension.
Atomoxetine is also available in the form of oral suspension. In the form of oral suspension, it is available in the dosage strengths of 30mg, 60mg, and 75mg capsules.
Brand name:Strattera (Atomoxetine)
by Drugs.com on Aug 13, 2024. Written by.
Strattera (Atomoxetine HCL) is used to treat attention deficit hyperactivity disorder (ADHD) in children ages 6-11 years. It may also be used in adults and adolescents for the treatment of ADHD in adults and children 12 years of age and older.
Strattera may also be used for the treatment of narcolepsy and as a sleep aid for children 12 years of age and older. It is also used to treat insomnia in adults and adolescents.
Strattera may cause low mood or sleepiness in some children. It may also cause irritability, drowsiness, dry mouth, dizziness, tiredness, drowsiness, weight gain, or irritability.
Strattera may be used alone or in combination with other medicines to treat ADHD in adults and children 12 years of age and older.
Strattera may cause drowsiness, dizziness, drowsiness, dry mouth, sleepiness, weight gain, or irritability. Do not drive, operate machinery, or do any other activity that requires alertness or coordination until you can determine if Strattera is the right treatment for you.
Strattera is not approved for the treatment of ADHD in children.
Tell your healthcare provider about all your medical conditions, including if you:
Take Strattera exactly as prescribed by your healthcare provider. Follow your healthcare provider's directions exactly. Do not change your dose or stop taking Strattera suddenly.
Take Strattera at the same time each day as directed by your healthcare provider.
Inform your healthcare provider if you have heart problems, high or low blood pressure, liver problems, diabetes, high cholesterol, or a family history of high blood pressure. Strattera should be taken at the same time each day.
If you miss a dose of Strattera, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed dose.
If you are taking a higher dose of Strattera (10 mg or 20 mg), you should not take this medication to treat ADHD. You may need to take this medication to treat high blood pressure or diabetes. This medication is not approved for use in children under 6 years of age.
Strattera may cause changes in the brain chemistry when used in combination with other medications. It may also cause changes in the brain chemistry when used in combination with stimulant drugs.
Stade de France Pharmacy